Metraipolis › archive › dc_7d7f431fee3c

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial — Europe PMC PMID:42786443

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42786443
DOI
10.1186/s12885-[numero omesso]-3
License (as archived)
solo-consultazione
Archived
2026-10-31T10:00:03.631Z
SHA-256 of the archived text
79bcbcd8ef19bd01d48a675ec39696f19954daa566a2d25313e26441c13ba0ca
Stable URL of this page
https://metraipolis.com/documento/dc_7d7f431fee3c

How to cite

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial — Europe PMC PMID:42786443 — Europe PMC (en), https://europepmc.org/article/MED/42786443 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7d7f431fee3c (Metraipolis archive dc_7d7f431fee3c, sha256 79bcbcd8ef19bd01d48a675ec39696f19954daa566a2d25313e26441c13ba0ca)
BibTeX
@misc{dc7d7f431fee3c,
  title = {Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial — Europe PMC PMID:42786443},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42786443},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7d7f431fee3c; sha256 79bcbcd8ef19bd01d48a675ec39696f19954daa566a2d25313e26441c13ba0ca},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42786443. Agents can read the archived copy with the MCP tool read_document.